This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The company expects to launch this product through its marketing partner in the near future
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The portfolio includes branded injectable cephalosporines for infectious diseases
The IND application supports the next phase of development of SBO-154
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated